Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy

Hypertension Research

Volumn 38, Issue 5, 2015, Pages 361-366

  Luizon, Marcelo R ^a   Belo, Vanessa A ^a   Palei, Ana C T ^b   Amaral, Lorena M ^a   Lacchini, Riccardo ^a   Sandrim, Valeria C ^c   Duarte, Geraldo ^a   Cavalli, Ricardo C ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

adipocytokine; gestational hypertension; haplotypes; NAMPT; preeclampsia; visfatin

Indexed keywords

ADIPOCYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; BLOOD; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; PREGNANCY; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADULT; CYTOKINES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRE-ECLAMPSIA; PREGNANCY; YOUNG ADULT;

EID: 84929085277     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2015.15     Document Type: Article

References (41)

1. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25: 391-403.
2. Palei AC, Spradley FT, Warrington JP, George EM, Granger JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf) 2013; 208: 224-233.
3. Warrington JP, George EM, Palei AC, Spradley FT, Granger JP. Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension 2013; 62: 666-673.
4. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V Pre-eclampsia and future cardiovascular risk among women: a review. J Am Coll Cardiol 2014; 63: 1815-1822
5. Carty DM, Delles C, Dominiczak AF. Preeclampsia and future maternal health. J Hypertens 2010; 28: 1349-1355.
6. Jeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev 2013; 71: S18-S25.
7. Roberts JM, Bodnar LM, Patrick TE, Powers RW. The role of obesity in preeclampsia. Pregnancy Hypertens 2011; 1: 6-16.
8. Mori T, Shinohara K, Wakatsuki A, Watanabe K, Fujimaki A. Adipocytokines and endothelial function in preeclamptic women. Hypertens Res 2010; 33: 250-254.
9. Tersigni C, Di Nicuolo F, D'Ippolito S, Veglia M, Castellucci M, Di Simone N. Adipokines: new emerging roles in fertility and reproduction. Obstet Gynecol Surv 2011; 66: 47-63.
10. Briana DD, Malamitsi-Puchner A. Reviews: adipocytokines in normal and complicated pregnancies. Reprod Sci 2009; 16: 921-937.
11. Miehle K, Stepan H, Fasshauer M. Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin Endocrinol (Oxf) 2012; 76: 2-11.
12. Van de Voorde J, Pauwels B, Boydens C, Decaluwe K. Adipocytokines in relation to cardiovascular disease. Metabolism 2013; 62: 1513-1521.
13. Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 2012; 32: 229-243.
14. Peiro C, Romacho T, Carraro R, Sanchez-Ferrer CF. Visfatin/PBEF/Nampt: a new cardiovascular target? Front Pharmacol 2010; 1: 135.
15. Romacho T, Sanchez-Ferrer CF, Peiro C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013; 2013: 946427.
16. Adali E, Yildizhan R, Kolusari A, Kurdoglu M, Bugdayci G, Sahin HG, Kamaci M. Increased visfatin and leptin in pregnancies complicated by pre-eclampsia. J Matern Fetal Neonatal Med 2009; 22: 873-879.
17. Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, Lossner U, Bluher M, Stumvoll M, Faber R, Stepan H. Serum levels of the adipokine visfatin are increased in pre-eclampsia. Clin Endocrinol (Oxf) 2008; 69: 69-73.
18. Ferreira AF, Rezende JC, de Cassia COR, Akolekar R, Nicolaides KH. Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia. J Hum Hypertens 2013; 27: 261-264.
19. Zorba E, Vavilis D, Venetis CA, Zournatzi V, Kellartzis D, Tarlatzis BC. Visfatin serum levels are increased in women with preeclampsia: a case-control study. J Matern Fetal Neonatal Med 2012; 25: 1668-1673.
20. Zulfikaroglu E, Isman F, Payasli A, Kilic S, Kucur M, Danisman N. Plasma visfatin levels in preeclamptic and normal pregnancies. Arch Gynecol Obstet 2010; 281: 995-998.
21. Hu W, Wang Z, Wang H, Huang H, Dong M. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 413-418.
22. Kim SC, Park MJ, Joo BS, Joo JK, Suh DS, Lee KS. Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia. J Obstet Gynaecol Res 2012; 38: 665-673.
23. Mazaki-Tovi S, Romero R, Kim SK, Vaisbuch E, Kusanovic JP, Erez O, Chaiworapongsa T, Gotsch F, Mittal P, Nhan-Chang CL, Than NG, Gomez R, Nien JK, Edwin SS, Pacora P, Yeo L, Hassan SS. Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA? J Matern Fetal Neonatal Med 2010; 23: 857-868.
24. Romao M, Weel IC, Lifshitz SJ, Peracoli MT. Elevated hyaluronan and extracellular matrix metalloproteinase inducer levels in women with preeclampsia. Arch Gynecol Obstet 2014; 289: 575-579.
25. Belo VA, Luizon MR, Lacchini R, Miranda JA, Lanna CM, Souza-Costa DC, Tanus-Santos JE. The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity. Int J Obes (Lond) 2015; 39: 130-135.
26. Leander K, Gigante B, Silveira A, Vikstrom M, Hamsten A, Hogberg J. NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction. Clin Chim Acta 2012; 413: 727-732.
27. Tabassum R, Mahendran Y, Dwivedi OP, Chauhan G, Ghosh S, Marwaha RK, Tandon N, Bharadwaj D. Common variants of IL6, LEPR, and PBEF1 are associated with obesity in Indian children. Diabetes 2012; 61: 626-631.
28. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
29. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. BMC Genet 2008; 9: 36.
30. Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R, Nadruz W Jr, Tanus-Santos JE. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens 2012; 26: 171-177.
31. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
32. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-4791.
33. Mori T, Watanabe K, Iwasaki A, Kimura C, Matsushita H, Shinohara K, Wakatsuki A. Differences in vascular reactivity between pregnant women with chronic hypertension and preeclampsia. Hypertens Res 2014; 37: 145-150.
34. Pimentel AM, Pereira NR, Costa CA, Mann GE, Cordeiro VS, de Moura RS, Brunini TM, Mendes-Ribeiro AC, Resende AC. L-arginine-nitric oxide pathway and oxidative stress in plasma and platelets of patients with pre-eclampsia. Hypertens Res 2013; 36: 783-788.
35. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, Weng S, Cherry JM, Snyder M. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012; 22: 1790-1797.
36. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001; 26: 107-117.
37. Adyshev DM, Elangovan VR, Moldobaeva N, Mapes B, Sun X, Garcia JG. Mechanical stress induces pre-B-cell colony-enhancing factor/NAMPT expression via epigenetic regulation by miR-374a and miR-568 in human lung endothelium. Am J Respir Cell Mol Biol 2014; 50: 409-418.
38. Zhang YY, Gottardo L, Thompson R, Powers C, Nolan D, Duffy J, Marescotti MC, Avogaro A, Doria A. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 2006; 14: 2119-2126.
39. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, Hudson TJ, Bouchard C, Gaudet D, Pérusse L, Vohl MC, Engert JC. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006; 55: 2896-2902.
40. Bottcher Y, Teupser D, Enigk B, Berndt J, Klöting N, Schön MR, Thiery J, Blüher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab 2006; 91: 2725-2731.
41. Luizon MR, Sandrim VC, Palei AC, Lacchini R, Cavalli RC, Duarte G, Tanus-Santos JE. Epistasis among eNOS, MMP-9 and VEGF maternal genotypes in hypertensive disorders of pregnancy. Hypertens Res 2012; 35: 917-921.